CytoSorbents to Report Fiscal 2020 Operating and Financial Results

Rhea-AI Summary

CytoSorbents Corporation (NASDAQ: CTSO) will announce its Q4 2020 and fiscal 2020 financial results on March 9, 2021 at 4:45 PM EST. Management will host a conference call to discuss operational and financial achievements, as well as a Q&A session. CytoSorbents specializes in critical care immunotherapy with its flagship product, CytoSorb®, approved in the EU, utilized in over 121,000 treatments worldwide. The company has received significant funding of over $38 million for its innovative blood purification technologies.

Positive

• CytoSorbents will report financial results that may reflect operational growth.
• CytoSorb® has been utilized in over 121,000 treatments, indicating strong market acceptance.
• The company has received over $38 million in non-dilutive funding for its technologies.

Negative

• None.

MONMOUTH JUNCTION, N.J., March 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report fiscal 2020 financial results on Tuesday, March 9, 2021 at 4:45PM EST. 

CytoSorbents Corporation to Report Q4 2020 and Fiscal 2020 Operating and Financial Results on Tuesday, March 9, 2021

CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q4 2020 and fiscal year ending December 31, 2020 followed by a question and answer session.

Conference Call Details:
Date: Tuesday, March 9, 2021
Time: 4:45 PM Eastern
Participant Dial-In:  201-389-0879
Conference ID:  13716351
Live Presentation Webcast:  http://public.viavid.com/index.php?id=143499

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.  There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: http://public.viavid.com/index.php?id=143499

http://public.viavid.com/index.php?id=108451http://public.viavid.com/index.php?id=105816An archived recording and written transcript of the conference call will be available under the Investor Relations section of the Company's website at http://cytosorbents.com/investor-relations/financial-results/

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 67 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist.  CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 121,000 human treatments to date.  CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma), and both ticagrelor and rivaroxaban during cardiothoracic surgery.  CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.  CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ™, K⁺ontrol™, DrugSorb™, ContrastSorb, and others.    For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter

 

Cytosorbents Contact: Amy Vogel 732-398-5394 avogel@cytosorbents.com

Public Relations Contact: Eric Kim Rubenstein Public Relations 212-805-3052 ekim@rubensteinpr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/cytosorbents-to-report-fiscal-2020-operating-and-financial-results-301237907.html

SOURCE CytoSorbents Corporation

FAQ

When will CytoSorbents report its Q4 2020 results?

CytoSorbents will report its Q4 2020 results on March 9, 2021.

What time is the CytoSorbents conference call on March 9, 2021?

The conference call will be held at 4:45 PM EST on March 9, 2021.

What is CytoSorbents' main product?

CytoSorbents' main product is CytoSorb®, a blood purification technology.

How many treatments has CytoSorb® been used in?

CytoSorb® has been used in over 121,000 human treatments globally.

How much funding has CytoSorbents received for its technologies?

CytoSorbents has received more than $38 million in funding for its technologies.